299 related articles for article (PubMed ID: 28104622)
1. Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials.
Bangalore S; Fakheri R; Wandel S; Toklu B; Wandel J; Messerli FH
BMJ; 2017 Jan; 356():j4. PubMed ID: 28104622
[TBL] [Abstract][Full Text] [Related]
2. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials.
Xie X; Liu Y; Perkovic V; Li X; Ninomiya T; Hou W; Zhao N; Liu L; Lv J; Zhang H; Wang H
Am J Kidney Dis; 2016 May; 67(5):728-41. PubMed ID: 26597926
[TBL] [Abstract][Full Text] [Related]
3. Renin-Angiotensin System Inhibitors in Patients With COVID-19: A Meta-Analysis of Randomized Controlled Trials Led by the International Society of Hypertension.
Gnanenthiran SR; Borghi C; Burger D; Caramelli B; Charchar F; Chirinos JA; Cohen JB; Cremer A; Di Tanna GL; Duvignaud A; Freilich D; Gommans DHF; Gracia-Ramos AE; Murray TA; Pelorosso F; Poulter NR; Puskarich MA; Rizas KD; Rothlin R; Schlaich MP; Schreinlecher M; Steckelings UM; Sharma A; Stergiou GS; Tignanelli CJ; Tomaszewski M; Unger T; van Kimmenade RRJ; Wainford RD; Williams B; Rodgers A; Schutte AE;
J Am Heart Assoc; 2022 Sep; 11(17):e026143. PubMed ID: 36000426
[TBL] [Abstract][Full Text] [Related]
4. Association between early worsening of kidney function and poor outcomes in patients treated with renin angiotensin system inhibitors: A meta-analysis.
Yuan S; Liu Y; He W; Jin J; Liu L; He Q
Nephrology (Carlton); 2021 Oct; 26(10):772-781. PubMed ID: 34165226
[TBL] [Abstract][Full Text] [Related]
5. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.
Tai C; Gan T; Zou L; Sun Y; Zhang Y; Chen W; Li J; Zhang J; Xu Y; Lu H; Xu D
BMC Cardiovasc Disord; 2017 Oct; 17(1):257. PubMed ID: 28982370
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials.
Hoang V; Alam M; Addison D; Macedo F; Virani S; Birnbaum Y
Cardiovasc Drugs Ther; 2016 Apr; 30(2):189-98. PubMed ID: 26861251
[TBL] [Abstract][Full Text] [Related]
7. Sex differences in efficacy of pharmacological therapies in heart failure with reduced ejection fraction: a meta-analysis.
Danielson C; Lileikyte G; Ouwerkerk W; S P Lam C; Erlinge D; Teng TK
ESC Heart Fail; 2022 Aug; 9(4):2753-2761. PubMed ID: 35603531
[TBL] [Abstract][Full Text] [Related]
8. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials.
Bangalore S; Fakheri R; Toklu B; Ogedegbe G; Weintraub H; Messerli FH
Mayo Clin Proc; 2016 Jan; 91(1):51-60. PubMed ID: 26763511
[TBL] [Abstract][Full Text] [Related]
10. Association between renin-angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study.
Savarese G; Dahlström U; Vasko P; Pitt B; Lund LH
Eur Heart J; 2018 Dec; 39(48):4257-4265. PubMed ID: 30351407
[TBL] [Abstract][Full Text] [Related]
11. Renin-angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis.
Bang CN; Greve AM; Køber L; Rossebø AB; Ray S; Boman K; Nienaber CA; Devereux RB; Wachtell K
Int J Cardiol; 2014 Aug; 175(3):492-8. PubMed ID: 25012498
[TBL] [Abstract][Full Text] [Related]
12. Renin-angiotensin system blockade reduces cardiovascular events in nonheart failure, stable patients with prior coronary intervention.
Choi Y; Lim S; Lee KY; Park HW; Byeon J; Hwang BH; Kim JJ; Oh YS; Youn HJ; Jung WS; Seung KB; Chang K
Coron Artery Dis; 2018 Sep; 29(6):451-458. PubMed ID: 29489465
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials.
Makani H; Bangalore S; Desouza KA; Shah A; Messerli FH
BMJ; 2013 Jan; 346():f360. PubMed ID: 23358488
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
Danchin N; Cucherat M; Thuillez C; Durand E; Kadri Z; Steg PG
Arch Intern Med; 2006 Apr; 166(7):787-96. PubMed ID: 16606817
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: Systematic review and meta-analysis.
Salvador GL; Marmentini VM; Cosmo WR; Junior EL
Eur J Prev Cardiol; 2017 Dec; 24(18):1914-1924. PubMed ID: 28862020
[TBL] [Abstract][Full Text] [Related]
16. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials.
Bangalore S; Fakheri R; Toklu B; Messerli FH
BMJ; 2016 Feb; 352():i438. PubMed ID: 26868137
[TBL] [Abstract][Full Text] [Related]
17. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials.
Bangalore S; Kumar S; Wetterslev J; Messerli FH
BMJ; 2011 Apr; 342():d2234. PubMed ID: 21521728
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin-converting-enzyme inhibition in stable coronary artery disease.
Braunwald E; Domanski MJ; Fowler SE; Geller NL; Gersh BJ; Hsia J; Pfeffer MA; Rice MM; Rosenberg YD; Rouleau JL;
N Engl J Med; 2004 Nov; 351(20):2058-68. PubMed ID: 15531767
[TBL] [Abstract][Full Text] [Related]
20. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
Saha SA; Molnar J; Arora RR
Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
